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Aims To investigate the effect of surgical gastric bypass-induced weight loss and related alterations in endocannabinoids
(ECs) and adipocytokine plasma levels on coronary circulatory dysfunction in morbidly obese (MOB) individuals.
Methods
and results
Myocardial blood flow (MBF) responses to cold pressor test (CPT) from rest (DMBF) and during pharmacologically
induced hyperaemia were measured with 13N-ammonia PET/CT in 18 MOB individuals with a body mass index
(BMI) . 40 kg/m2 at baseline and after a median follow-up period of 22 months. Gastric bypass intervention
decreased BMI from a median of 44.8 (inter-quartile range: 43.3, 48.2) to 30.8 (27.3, 34.7) kg/m2 (P, 0.0001).
This decrease in BMI was accompanied by a marked improvement in endothelium-related DMBF to CPT and hyper-
aemic MBFs, respectively [0.34 (0.18, 0.41) from 0.03 (20.08, 0.15) mL/g/min, P ¼ 0.002; and 2.51 (2.17, 2.64) from
1.53 (1.39, 2.18) mL/g/min, P, 0.001]. There was an inverse correlation between decreases in plasma concentrations
of the EC anandamide and improvement in DMBF to CPT (r ¼ 20.59, P ¼ 0.009), while increases in adiponectin
plasma levels correlated positively with hyperaemic MBFs (r ¼ 0.60, P ¼ 0.050). Conversely, decreases in leptin
plasma concentrations were not observed to correlate with the improvement in coronary circulatory function
(r ¼ 0.22, P ¼ 0.400, and r ¼ 20.31, P ¼ 0.250).
Conclusions Gastric bypass-related reduction of BMI in MOB individuals beneficially affects coronary circulatory dysfunction.
The dysbalance between ECs and adipocytokines appears to be an important determinant of coronary circulatory
function in obesity.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Adipocytokines † Coronary circulation † Endocannabinoids † Endothelium † Myocardial blood flow † Obesity
† Positron emission tomography
Introduction
The prevalence of obesity in adults in the USA and in industrialized
countries continues to exceed 30% in most sex-age groups, and
6–8% have morbid or severe obesity [body mass index
(BMI) ≥ 40 kg/m2].1 Epidemiological investigations have demon-
strated that obesity is associated with increased cardiovascular
morbidity and mortality.2 In individuals with increasing body
weight, progressive worsening of coronary endothelial function
may ensue, while the functional abnormality may extend to an
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impairment of the total coronary vasodilator capacity in obesity.3
Although an impairment of coronary circulatory function has
been appreciated as functional precursor of the coronary athero-
sclerotic disease (CAD) process, the exact mechanism by which
obesity initiates and accelerates CAD is still poorly understood.
As we have recently shown,4 increased endocannabinoid (EC)
plasma levels of anandamide (AEA) and 2-arachidonoylglycerol
(2-AG), which are predominantly produced and released from
the adipose tissue in obese individuals, are associated with coron-
ary circulatory dysfunction. This observation may suggest increases
in EC plasma levels as a novel endogenous cardiovascular risk
factor in obesity. Interestingly, in morbid obesity, potential
adverse effects of ECs and insulin-resistant syndrome on coronary
circulatory function appear to be balanced, at least in part, by a
seven-fold increase in leptin plasma levels.5 Yet, the role of
leptin to alter coronary circulatory function still remains a matter
of ongoing debate.3 Also, adiponectin as another adipocytokine has
been widely realized to exert beneficial effects on the function of
the coronary circulation.6 Weight loss by lifestyle interventions
combined with anti-obesity medications or gastric bypass,
however, has been demonstrated to improve endothelial function
of the peripheral circulation in obese or morbidly obese (MOB)
individuals.7,8 The effect of gastric bypass-induced weight loss on
ECs, adipocytokines, and coronary circulatory dysfunction in
MOB individuals, however, still remains to be characterized.
With this in mind, we investigated whether surgical bypass-
induced weight loss in MOB individuals (BMI ≥ 40 kg/m2) improves
coronary circulatory dysfunction after a follow-up (FU) period of
at least 12 months and how this beneficial effect on the coronary
circulation is related to changes in body weight, EC, adiponectin,
and leptin plasma levels.
Methods
Study population and design
In a prospective, baseline, and longitudinal FU study, coronary circula-
tory function was assessed with 13N-ammonia and PET/CT (64-slice
Biograph HiRez TruePoint PET-CT scanner, Siemens, Erlangen,
Germany) by measuring myocardial blood flow (MBF) at rest and its
response to vasomotor stress in 18 MOB individuals (BMI ≥ 40 kg/
m2) without arterial hypertension, hypercholesterolaemia, smoking,
and diabetes mellitus before and after a FU of at least 12 months of
gastric bypass (bariatric) surgery as a weight reduction treatment.9
The standard operation involved Roux-en-Y gastric bypass surgery
with an isolated gastric pouch ,2 ounces and a 100 cm distal bowel
limb. In addition, MBF values were compared with those in 18
healthy, normal weight, age- and gender-matched controls (CON;
BMI , 25 kg/m2), who served as reference to define the normal
range of coronary circulatory function. Among the initial 25 MOB indi-
viduals who underwent PET baseline examination,5 18 repeated the
PET examination after an FU of at least 12 months (median FU: 22
months and inter-quartile range, IQR: 14–28 months), while 7 MOB
individuals did not repeat study examinations simply for convenience
and lack of interest. Study applicants were recruited only for study
purpose in the absence of any cardiac or vasoactive medication such
as angiotensin-converting enzyme inhibitors, angiotensin II receptor
blockers, calcium channel blockers, statins, or b-blockers, a history
of variant angina, a family history of premature CAD, current or pre-
vious smoking, or clinically manifested cardiovascular or any other sys-
temic disease. In addition, throughout the study period, no cardiac or
vasoactive medication was initiated in any study participants. Following,
the applicants underwent an initial screening visit including a physical
examination, electrocardiogram, blood pressure measurements, and
routine blood chemistry in a fasting state entailing lipid profile and
plasma levels of triglycerides, insulin, glucose, high-sensitive C-reactive
protein (CRP), and haemoglobin Alc. Physical examination and electro-
cardiogram were normal in all study applicants. In addition, study
applicants with evidence of left ventricular hypertrophy on echocardi-
ography were not recruited for current study. Subsequently, each
study participant underwent dual X-ray absorptiometry (Hologic
QDR4500A, Hologic, Bedford, MA, USA) to measure body compos-
ition, total fat burden, and fat distribution.5 This was followed by
13N-ammonia PET/CT assessment of myocardial perfusion and MBF.
A prerequisite for the study inclusion was a normal stress–rest perfu-
sion imaging on 13N-ammonia PET/CT, which widely excluded the
presence of flow-limiting CAD lesions. Controls and all MOB indivi-
duals were part of previous baseline investigations determining the
effect of altered EC, adiponectin, and leptin plasma levels in obesity
and morbid obesity on coronary circulatory function.4,5 Routine
blood chemistry, EC such as AEA and 2-AG, adiponectin, and leptin
plasma levels were assessed as previously described.4 The study was
approved by the University Hospitals of Geneva Institutional Review
Board (No. 07-183), and each participant signed the approved
informed consent form.
PET/CT assessment of myocardial perfusion
and flow
Myocardial perfusion and MBF, measured in mL/min/g, were deter-
mined with 13N-ammonia PET/CT, serial PET image acquisition, and
a two-compartment tracer kinetic model as described previously.4
The gated PET emission data were used for the analysis of the relative
13N-ammonia uptake of the left ventricle, and thus, myocardial perfu-
sion was evaluated visually on reoriented short- and long-axis myocar-
dial slices and semi-quantitatively on the corresponding polar map
from the last static 18 min transaxial PET image. For the semi-
quantitative analysis of the PET perfusion images, a 17-segment
model and a 5-point grading system by two expert observers were
used.4 Myocardial blood flow was measured at rest, during sympathetic
stimulation with cold pressor testing (CPT), reflecting predominantly
endothelium-dependent circulatory function, and during dipyridamole-
stimulated hyperaemic flow increases (140 mg/kg/min dipyridamole),
reflecting predominantly flow increases due to vascular smooth
muscle relaxation of coronary arteriolar vessel.3 The increase in MBF
from rest to CPT was defined as endothelium-related DMBF
(mL/min/g). The myocardial flow reserve (MFR) was calculated as
the ratio of adenosine MBF over rest MBF. Heart rate, blood pressure,
and a 12-lead electrocardiogram were recorded continuously during
each MBF measurement. The rate–pressure product (RPP), which is
a product of the mean heart rate and systolic blood pressure (SBP)
during the first 2 min of image acquisition, served as an index of
cardiac work. Further, to account for possible interindividual variations
in coronary driving pressure, an index of global coronary vascular re-
sistance (CVR) was determined as the ratio of mean arterial
blood pressure (mmHg) to MBF (mL/g/min). In addition, MBF was nor-
malized to the RPP, and thus myocardial work (averaged during
the first 2 min of image acquisition; NMBF ¼ MBF divided by RPP
multiplied by 10 000).
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Statistics
Because continuous variables are not always normally distributed, they
are presented as median and IQR (25th to 75th percentile: quartile 1,
quartile 3). For comparison of differences between MOB individuals
and CON, we used the Mann–Whitney U test for independent
samples (SAS Institute, Cary, NC, USA), while when analysing differ-
ences between MOB-baseline and MOB-FU, we used the Wilcoxon
test for related samples. A comparison of CPT-induced change in
MBF and dipyridamole MBFs among the different groups was per-
formed by one-way analysis of variance followed by Scheffe multiple
comparison tests. Pearson correlation coefficients (r), assuming
a linear regression and the standard error of the estimate, were calcu-
lated to investigate the associations between CPT- and dipyridamole-
induced changes in MBFs and laboratory parameters. All test proce-
dures were two-tailed, and P ≤ 0.05 was considered statistically
significant. Using an SD of 0.18 of DMBF to vasomotor stress, and
a minimum clinically relevant difference in DMBF of 0.20 in flow
response, a ¼ 0.05, and a power (1 2 b) of 0.8, a minimum sample
size of 10 individuals was estimated to be needed for repeat long-term
PET flow studies.10,11
Clinical characteristics, haemodynamics,
and myocardial blood flow measurements
at baseline
The clinical characteristics, anthropometrical measurements, and
dual X-ray absorptiometry-determined total fat burden and fat
distribution of the study groups can be appreciated in Table 1. There
were no significant differences in clinical characteristics, haemodynam-
ics, and MBFs in MOB groups with and without FU at baseline (Tables 1
and 2). Thus, there are no baseline characteristics that could be
identified (with the given power/sample size) to have influenced lack
of FU.
Resting heart rate was higher in MOB individuals than in CON, while
SBP did not differ significantly (Table 2). Due to the higher heart rate at
rest in MOB individuals, the resting RPP was significantly higher in
MOB individuals than in CON. The higher RPP at rest in MOB indivi-
duals was associated with a significantly higher resting MBF than
in CON (Table 2). When adjusted for the RPP, the normalized
MBF (NMBF) at rest, however, was comparable among groups.
CPT-induced sympathetic stimulation did lead to a significant increase
in the heart rate and SBP in each group, so that the RPP was significant-
ly higher during CPT than at baseline (Table 2). CPT-related increase in
SBP, however, was higher in MOB individuals than in CON, while it
was comparable for the heart rates. Although the RPP during CPT
was also higher in MOB individuals than in CON, MBFs during CPT
tended to be lower in MOB than in CON individuals. When adjusted
for RPP, the NMBF during CPT was significantly lower in MOB indivi-
duals than in CON. Further, when looking at the CPT-related increase
in RPP from rest (DRPP), it was comparable between CON and MOB
individuals, whereas the corresponding change in MBF from rest to
CPT (DMBF) was significantly less in MOB individuals than in CON
(Table 2, Figure 1A). Thus, despite comparable increases in cardiac
work with CPT, the endothelium-related change in MBF was signifi-
cantly impaired in MOB individuals. These observations are further
substantiated by evaluating changes in CVR to CPT. As can be seen
further in Table 2, changes of CVR mirrored those of MBF for each
study group. The observed differences in haemodynamic responses
therefore did not account for altered MBF responses to CPT. With
regard to dipyridamole-stimulated hyperaemic MBFs and MFR, they
were significantly lower in MOB individuals than in CON (Table 2,
Figure 1B). Further, we related hyperaemic MBFs to the mean arterial
blood pressure in order to account for potential interindividual varia-
tions in coronary driving pressure. The resulting CVR during dipyrid-
amole stimulation was abnormally increased when compared with
CON.
Follow-up studies after gastric bypass-induced
weight loss in morbidly obese individuals
As expected, gastric bypass surgery produced a median decrease of
31.8% (28.3, 36.5) in BMI and 50.5% (41.7, 61.8) in fat mass, respect-
ively (Table 1). While nine of the initial MOB individuals had achieved
BMI , 30 kg/m2, nine remained between 30 and 35 kg/m2. After FU,
plasma total cholesterol, LDL cholesterol, triglyceride, glucose,
insulin, HOMA, and CRP had significantly declined from baseline in
MOB individuals, whereas HDL cholesterol had increased (Table 1).
The gastric bypass-induced weight loss was paralleled by a significant
decrease in AEA, 2-AG, and leptin plasma levels. Contrary to this,
weight loss resulted in a significant increase in adiponectin plasma at
the FU. In addition, AEA and 2-AG plasma levels after the FU were
lower (P ¼ 0.792 and P ¼ 0.012), while leptin and adiponectin
plasma levels were higher when compared with CON (P ¼ 0.550
and P ¼ 0.035).
Haemodynamics and myocardial blood flow
measurements at follow-up
Also at the FU, 13N-ammonia PET rest–stress perfusion examination
was normal in all MOB individuals. Resting heart rate, SBPs, and
RPPs were lower at the FU than at baseline in MOB individuals
(Table 2). As a consequence, resting MBF on repeat assessment
tended to be lower. When adjusted for the RPP, however, the
NMBF at rest was similar between baseline and FU examination
(Table 2). During sympathetic stimulation with CPT, heart rate, SBPs,
and RPPs were also significantly lower at the FU than at baseline. Con-
versely, MBFs during CPT were significantly higher at the FU than at
baseline. This improvement in CPT-related MBFs during the FU was
also confirmed when MBFs were adjusted for RPP. Also here, the
NMBF during CPT was significantly higher at the FU than at baseline.
Further, the CPT-related increase in RPP from rest (DRPP) between
baseline and FU examination did not differ significantly, while the
DMBF to CPT was significantly higher at the FU when compared
with baseline (Table 2, Figure 1A). This improvement in endothelium-
related DMBF was comparable with those of CON (Figure 1A). As
regards dipyridamole-stimulated hyperaemic MBFs at the FU, they
were also observed to be significantly higher than at baseline and com-
parable with those of CON (Table 2, Figure 1B). The improvement in
hyperaemic MBFs after the FU was also paralleled by a significant
decrease in CVR at the FU when compared with baseline in MOB
individuals.
Comparison of myocardial blood flow
responses, changes in body fat,
adipocytokines, and endocannabinoid
concentrations
Alterations in routine blood chemistry, EC such as AEA and 2-AG, adi-
ponectin, and leptin plasma levels from baseline to the FU were
expressed as the difference in concentrations at baseline and the FU.
Changes in BMI, fat mass, and laboratory parameters in MOB indivi-
duals were compared with those of improvement in the flow response
to CPT and dipyridamole stimulation, respectively. These changes
were defined as the difference in DMBF to CPT and hyperaemic
MBF between the FU and baseline (e.g. difference in DMBF to
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Table 1 Characteristic of the study population
CON MOB base only MOB base P-value vs.
CON
P-value vs.
MOB base only
MOB follow-up P-value vs.
MOB base
Age, years 41 (36, 47) 46 (41, 51) 43 (36, 52) 0.317 0.463 44 (37, 53) 0.0001
Gender, F/M 8/10 3/4 8/10 8/10
Total fat amount, g 12 461 (9906, 15 470) 62 484 (51 240, 67 359) 57 009 (50 469, 61 180) 0.0001 0.072 28 222 (19 288, 35 677) 0.0001
BMI, kg/m2 22 (21, 23) 44 (41, 46) 45 (43, 49) 0.0001 0.084 31 (28, 35) 0.0001
Percentage of body fat, % 20 (15, 26) 49 (44, 51) 45 (41, 49) 0.0001 0.443 29 (25, 40) 0.0001
Central fat distribution 0.40 (0.38, 0.44) 0.55 (0.50, 0.57) 0.56 (0.46, 0.62) 0.0001 0.425 0.50 (0.42, 0.52) 0.001
Waist, cm 82 (80, 85) 132 (127, 143) 124 (119, 139) 0.0001 0.315 100 (96, 103) 0.012
Waist/hip ratio 0.84 (0.81, 0.88) 0.99 (0.96, 1.09) 0.91 (0.82, 1.01) 0.539 0.147 0.83 (0.80, 0.92) 0.012
AEA, ng/mL 0.56 (0.49, 0.68) 0.74 (0.69, 0.82) 0.70 (0.58, 0.93) 0.016 0.540 0.5 (0.5, 0.7) 0.003
2-AG, ng/mL 1.80 (1.00, 5.70) 3.03 (1.6, 4.7) 2.9 (1.3, 4.4) 0.753 0.599 1.0 (0.8, 1.4) 0.001
Leptin, ng/mL 4.5 (1.9, 10.1) 142.9 (59.3, 159.8) 101.3 (67.0, 113.7) 0.0001 0.240 7.2 (3.5, 13.4) 0.0001
Adiponectin, ng/mL 3.4 (2.0, 5.3) 0.41 (0.3, 0.5) 2.6 (2.1, 3.8) 0.207 0.067 6.0 (2.2, 10.5) 0.007
Cholesterol levels, mg/dL 191 (168, 238) 169 (162, 192) 180 (157, 201) 0.231 0.464 144 (123, 177) 0.006
LDL level, mg/dL 128 (106, 148) 111 (104, 130) 118 (99, 130) 0.066 0.931 77 (65, 98) 0.0001
HDL level, mg/dL 55 (39, 63) 42 (39, 42) 43 (37, 54) 0.095 0.118 49 (43, 81) 0.018
Triglyceride level, mg/dL 54 (48, 106) 77 (60, 99) 115 (81, 144) 0.0001 0.378 77 (55, 99) 0.001
Glucose level, mg/dL 94 (83, 103) 103 (85, 120) 99 (95, 111) 0.024 0.691 86 (75, 96) 0.004
Insulin, mUI/L 2.8 (1.9, 5.0) 16.4 (10.8, 24.9) 21.3 (6.0, 28.6) 0.0001 0.899 4.1 (1.9, 10.0) 0.005
HOMA 0.7 (0.5, 1.2) 3.7 (2.7, 6.7) 5.0 (0.8, 8.6) 0.004 0.851 0.9 (0.4, 3.5) 0.005
C-reactive protein levels, mg/L 0.9 (0.9, 3.0) 10.2 (7.5, 15.5) 6.5 (3.3, 9.5) 0.0001 0.512 0.9 (0.9, 1.4) 0.003
HbAlc, % 5.2 (5.0, 5.5) 5.3 (5.2, 5.4) 5.4 (5.3, 5.7) 0.053 0.219 5.1 (4.8, 5.2) 0.007
Values are median (Q1, Q3). Base, baseline examination; CON, controls; MOB, morbid obesity; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; BMI, body mass index; bAlc, haemoglobin Alc; HDL, high-density lipoprotein; HOMA,
homeostasis model assessment; LDL, low-density lipoprotein.
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Table 2 Haemodynamic and myocardial blood flow findings during PET/CT examinations
Groups
CON MOB base only MOB base P-value vs.
CON
P-value vs. MOB
base only
MOB follow-up P-value vs.
MOB base
Haemodynamics at rest
Heart rate (b.p.m.) 61 (53, 69) 68 (61, 73) 68 (66, 78) 0.010 0.454 60 (57, 69) 0.067
SBP (mmHg) 114 (109, 123) 123 (114, 126) 115 (110, 128) 0.486 0.605 106 (103, 119) 0.006
RPP 6745 (6192, 7749) 8317 (6941, 9444) 8144 (7310, 9354) 0.018 0.842 6601 (5806, 8056) 0.031
CPT
Heart rate (b.p.m.) 70 (63, 84) 79 (73, 86) 74 (69, 84) 0.330 0.514 70 (61, 80) 0.0001
P-value vs. heart rate at rest 0.0001 0.022 0.046 0.001
SBP (mmHg) 135 (125, 142) 151 (147, 159) 148 (131, 158) 0.013 0.288 134 (120, 140) 0.008
P-value vs. SBP at rest 0.0001 0.0001 0.001 0.001
RPP 9088 (8618, 10 824) 1232 (11 233, 13 525) 10 902 (9588, 11 801) 0.007 0.295 8911 (7860, 11 200) 0.022
P-value vs. RPP at rest 0.0001 0.0004 0.001 0.001
DRPP (CPT-rest) 2469 (1693, 3192) 3711 (2812, 4411) 2813 (1283, 3823) 0.581 0.199 1989 (1765, 3672) 0.744
Pharmacological vasodilation
Heart rate (b.p.m.) 85.0 (73, 91) 93 (83, 100) 84 (75, 100) 0.645 0.345 91 (80, 94) 0.422
P-value vs. heart rate at rest 0.0001 0.0002 0.001 0.002
SBP (mmHg) 114 (105, 118) 124 (120, 131) 119 (112, 137) 0.028 0.656 101 (95, 122) 0.008
P-value vs. SBP at rest 0.050 0.362 0.528 0.480
RPP 8970 (8030, 10 375) 11 590 (10 199, 12 403) 11 418 (8850, 12 294) 0.029 0.319 9660 (8000, 11 011) 0.381
P-value vs. RPP at rest 0.0001 0.0002 0.002 0.005
DRPP (pharmacological rest) 1740 (1302, 2794) 3283 (2514, 3809) 2420 (1102, 4080) 0.528 0.259 2614 (892, 4576) 0.619
MBF (mL/min/g)
MBF at rest 0.69 (0.61, 0.78) 0.82 (0.78, 0.94) 0.87 (0.66, 1.02) 0.013 0.600 0.73 (0.66, 0.90) 0.396
NMBF at rest 0.95 (0.86, 1.14) 1.12 (1.05, 1.17) 1.05 (0.88, 1.16) 0.446 0.607 1.19 (0.99, 1.34) 0.170
MBF during CPT 1.00 (0.83, 1.19) 0.89 (0.77, 0.97) 0.93 (0.80, 0.98) 0.107 0.804 1.08 (0.91, 1.34) 0.034
P-value vs. MBF at rest 0.0001 0.596 0.298 0.0001
DMBF to CPT from rest 0.26 (0.23, 0.41) 0.07 (20.03, 0.14) 0.00 (20.11, 0.18) 0.0001 0.870 0.36 (0.18, 0.44) 0.001
NMBF during CPT 1.05 (0.92, 1.15) 0.80 (0.61, 0.89) 0.84 (0.64, 1.00) 0.001 0.739 1.11 (0.97, 1.42) 0.001
P-value vs. NMBF at rest 0.041 0.004 0.004 0.519
MBF during pharmacological vasodilation 2.39 (1.95, 2.57) 1.74 (1.57, 1.88) 1.53 (1.39, 2.18) 0.001 0.713 2.51 (2.17, 2.64) 0.001
P-value vs. MBF at rest 0.0001 0.0005 0.0001 0.0001
MFR 3.40 (3.00, 3.80) 1.95 (1.79, 2.25) 2.08 (1.59, 2.54) 0.0001 0.467 3.24 (2.33, 3.99) 0.004
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CPT ¼ DMBF to CPT FU2 DMBF to CPT baseline). As can be appre-
ciated in Table 3, although the decrease in BMI and fat mass after the
FU was paralleled by a normalization of coronary circulatory function,
no association was observed with the improvement in endothelium-
related MBF responses to CPT. Similarly, the gastric bypass-induced
alterations in 2-AG, adiponectin, leptin, CRP, lipid profile, triglycerides,
glucose, and HOMA did not correlate with the difference in DMBF to
CPT, while there was a significant association between the decrease in
AEA plasma levels and the improvement in endothelium-related MBF
responses to CPT (Figure 2A). In order to account for haemodynamic
differences between baseline and FU studies, we also related altera-
tions of DCVR to CPT to gastric bypass-induced weight loss and meta-
bolic parameters (Table 3). Indeed, the observed correlation was also
maintained when alterations in DCVR were related to the decrease in
AEA plasma levels. In addition, there was also a trend of association
between alterations in DCVR and the decrease in total fat amount
but it did not reach statistical significance (P ¼ 0.088). As regards the
increase in hyperaemic MBFs between baseline and the FU, it was
only significantly associated with the increase in adiponectin plasma
levels (Figure 2B), and inversely with the decrease in glucose plasma
levels (Table 3). When evaluating the corresponding change in CVR
during dipyridamole stimulation, it correlated only with the increase
in adiponectin plasma levels. In order to evaluate whether an improve-
ment in endothelium-related MBF response to CPT also contributed
to the observed increase in hyperaemic MBFs after the FU, we evalu-
ated a possible association between the difference in DMBF to CPT
and difference in hyperaemic MBF. Indeed, the difference in DMBF to
CPT significantly correlated with the difference in hyperaemic MBF
(r ¼ 0.50, P, 0.0001) (Figure 3).
Discussion
The results of the current investigation provide several unique
observations. At first, gastric bypass-induced weight loss in MOB
individuals widely normalized coronary circulatory dysfunction. In
addition, the decrease in ECs plasma levels of AEA, associated
with the weight loss, was closely associated with the normalization
of coronary endothelial function. This close association between
the decrease in EC plasma levels and improvement in endothelium-
related MBF response to CPT provides further evidence of adverse
effect of elevated EC plasma levels on obesity-related coronary
vasculopathy.4,5 Secondly, gastric bypass-induced weight loss in
MOB individuals was paralleled by a marked increase in adiponec-
tin plasma levels, which was significantly associated with the im-
provement in hyperaemic flow increases. Weight loss-induced
increases in adiponectin plasma levels, therefore, were associated
with relatively higher increases in hyperaemic flows, which could
possibly reflect a beneficial effect of adiponectin in concert with
the weight loss, and/or adiponectin-related but still undetermined
factors on total integrated coronary vasodilator capacity. Thirdly,
the decrease in leptin plasma levels with decreasing body weight
was not observed to be related to the improvement in coronary
circulatory function at the FU. This observation may emphasize
that beneficial effect of leptin plasma levels on endothelium-related
coronary function may operate predominantly in MOB individuals
with a seven-fold increase of its concentration to counterbalance
the adverse effects of obesity on coronary circulatory dysfunction
as described previously.5 Fourthly, as we observed a significant as-
sociation between the improvement in endothelium-related MBF
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response to CPT and hyperaemic MBFs, the increase in hyperaem-
ic MBFs after gastric bypass-induced weight loss appears to be
related by 24% to the concurrent improvement in flow-
mediated and, thus, endothelium-dependent coronary vasomotor
function. This consideration also accords with previous investiga-
tions,12 which have demonstrated that shear-sensitive components
of the coronary endothelium contribute through a flow-mediated
vasodilation by 20–25% to hyperaemic flow increases. Taken to-
gether, the weight loss-induced decrease in ECs and the increase
in adiponectin plasma levels in initial MOB individuals contribute,
at least in part, to the normalization of coronary circulatory func-
tion, demonstrating that the (dys)balance between ECs, adiponec-
tin, and leptin is an important determinant of coronary circulatory
function in obesity.
Morbidly obese individuals but without traditional cardiovascu-
lar risk factors such as smoking, hypercholesterolaemia, or arterial
hypertension were investigated aiming to exclude possibly con-
founding effects of these cardiovascular risk factors on coronary
circulatory function. The dramatic weight loss after a median FU
period of 22 months following gastric bypass surgery normalized
coronary circulatory function in these individuals when compared
with an age- and gender-matched CON population. Yet, nine indi-
viduals were still overweight with BMI , 30 kg/m2 and nine indivi-
duals were still in the lower range of obesity with a BMI between
30 and 35 kg/m2 after the FU. Thus, although this range of body
weight is commonly associated with an abnormal function of the
coronary circulation,3,4 in these initial MOB individuals, coronary
circulation was normalized after a median BMI decrease from 45
to 30 kg/m2. These observations may suggest some kind of positive
‘rebound’ phenomenon on coronary circulatory function after a
striking weight loss, whose exact underlying mechanisms remain
to be clarified. Of particular interest, ECs were lower, while
leptin and adiponectin plasma levels were higher after the FU
when compared with CON. This also did hold true for ECs and
adiponectin plasma levels when compared with findings in
overweight and obesity, respectively,5 while leptin plasma levels
were lower. Thus, the gastric bypass-related weight loss manifested
in a relative rebound phenomenon of ECs and adipocytokines,
which may explain, at least in part, the normalization of coronary
circulatory function despite the fact that initial MOB individuals
remained overweight or relatively obese. In addition, it is conceiv-
able that the gastric bypass-induced weight loss, associated with an
improvement in lipid profile, insulin resistance syndrome, and
reductions in arterial pressure, did lead to a marked reduction in
the formation of oxidative stress burden via NADPH oxidase, ab-
normalities in LDL subfractions and LDL oxidation, while at the
same time beneficial effects of increases in HDL cholesterol and
unopposed NOS activity may have prevailed. This, in fact, may
have led to a positive dysbalance in favour of endothelium-derived
nitric oxide formation and other yet-unknown mechanisms asso-
ciated with a normalization of coronary circulatory function.12
The marked reduction in body weight, therefore, may have con-
ferred an enhanced beneficial effect on the production and endo-
thelial release of atheroprotective nitric oxide within the arterial
wall, similar to the one that has been described for statin with-
drawal but in the other direction.13 Conceptually, the observations
of a normalization of coronary circulatory function after a marked
weight loss as compared with healthy CON could also reflect, at
least in part, an issue of statistical power. The sample size of 18
MOB individuals undergoing gastric bypass to reduce body
weight burden vs. 18 CON may simply not have been large
enough to identify these relatively small differences in MBF
responses to vasomotor stress given the relative weight differences
when compared with baseline values. On the other hand, a positive
rebound phenomenon on coronary circulatory function after
gastric bypass-induced weight loss appears to be consistent with
a recent one in MOB individuals with various traditional cardiovas-
cular risk factors and assessment of brachial artery function.7 A
mean decrease in BMI of 25% was accompanied by an improve-
ment in flow-mediated brachial artery dilation in the mean to 10%,
Figure 1 Myocardial blood flows (MBF) during vasomotor stress in controls (CON) and morbidly obese (MOB) individuals. Change in MBF
to cold pressor testing from rest (A) and in hyperaemic MBF (B) in CON and in MOB individuals at baseline and at the follow-up.
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Table 3 Determinants of alterations in myocardial blood flow response to vasomotor stress after follow-up in a univariate analysis
Difference Difference in DMBF to CPT Difference in DCVR to CPT Difference in hyperaemic MBF Difference in CVR during
hyperaemia
Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value
Log BMI 0.249 (21.383, 3.986) 0.319 0.285 (2204.09, 726.42) 0.251 20.174 (28.81, 4.52) 0.504 20.199 (2230.85, 102.94) 0.429
Log fat amount 0.236 (20.739, 1.827) 0.379 0.440 (230.95, 392.88) 0.088 20.133 (24.08, 2.59) 0.636 20.243 (2110.19, 43.11) 0.364
Log AEA 20.593 (21.830, 20.299) 0.009 20.576 (2317.21, 244.87) 0.012 0.285 (20.72, 2.43) 0.267 20.217 (280.98, 33.12) 0.387
Log 2-AG 20.103 (20.497, 0.335) 0.685 0.058 (265.10, 81.06) 0.820 0.158 (20.70, 1.27) 0.544 20.122 (231.39, 19.60) 0.631
Log adiponectin 0.135 (20.190, 0.315) 0.606 0.197 (228.26, 60.77) 0.449 0.597 (0.00, 1.16) 0.050 0.462 (20.784, 27.52) 0.052
Log leptin 0.218 (20.202, 0.478) 0.400 0.089 (251.79, 71.78) 0.735 20.305 (21.33, 0.37) 0.250 20.120 (226.40, 16.88) 0.646
Log glucose 20.146 (22.019, 1.137) 0.562 20.380 (2458.62, 58.15) 0.120 20.675 (27.863, 21.96) 0.003 20.406 (2164.64, 14.474) 0.095
Log HOMA 0.107 (20.470, 0.614) 0.768 0.277 (265.32, 136.58) 0.439 20.070 (21.25, 1.05) 0.847 20.073 (236.07, 30.15) 0.842
Log total cholesterol 0.136 (20.981, 1.668) 0.590 0.249 (2116.98, 336.68) 0.320 20.347(24.95, 0.97) 0.172 20.223 (2114.61, 45.59) 0.375
Log LDL cholesterol 0.151 (21.484, 0.820) 0.550 0.154(2142.21, 261.03) 0.541 20.273 (24.12, 1.31) 0.289 20.257 (2103.85, 34.54) 0.304
Log HDL cholesterol 0.172 (20.505, 1.002) 0.494 0.068 (2116.39, 150.79) 0.788 20.334 (22.94, 0.64) 0.191 20.121 (257.343, 35.930) 0.633
Log triglycerides 0.446 (20.040, 1.303) 0.064 0.379 (227.78, 215.54) 0.121 20.169 (22.43, 1.27) 0.516 0.123 (235.088, 56.446) 0.628
Log C-reactive protein 20.245 (20.742, 0.275) 0.343 20.283 (2144.68, 43.74) 0.271 20.274 (22.09, 0.70) 0.304 20.070 (241.27, 31.97) 0.790
MBF, myocardial blood flow; CPT, cold pressor testing; BMI, body mass index; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; SBP, systolic blood pressure; LDL cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, high-density
lipoprotein cholesterol; HOMA, homeostasis model assessment for insulin resistance.
P-values by analysis of variance, significance value P ≤ 0.05.
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which is substantially higher when compared with a flow-mediated
brachial artery dilation in the mean of 4.8% in a healthy study popu-
lation of 4739 adults.14 Yet, it remains to be answered whether the
observed improvement in, or normalization of, coronary circula-
tory function after a marked weight loss is sustained in the long-
term in these initial MOB individuals, who are otherwise still con-
sidered overweight or mildly obese. Most likely, behavioural inter-
ventions related to weight, diet, and physical activity may be
needed to stabilize the achieved normalization in coronary circula-
tory function.7,8
Notably, the aforementioned investigation in the assessment of
brachial artery function7 demonstrated a marked improvement in
endothelial function with a weight loss intervention after gastric
bypass in MOB individuals but with other, in part, medically
treated traditional cardiovascular risk factors, while the non-
endothelium vascular smooth muscle cell function was not
affected. Therefore, it is equally possible that the improvement in
brachial artery function was related not only to surgical weight
loss but also to an improved and medically treated cardiovascular
risk profile of diabetes mellitus, arterial hypertension, and hyper-
cholesterolaemia.7 In this scenario, the current study demonstrates
the first proof that gastric bypass-induced weight loss in MOB indi-
viduals, paralleled by alterations in lipid profile, a decrease in
plasma markers of the insulin resistance syndrome, and chronic in-
flammation, widely normalized not only endothelium-related MBF
responses to CPT but also hyperaemic flow reserve. In current and
previous investigation of brachial artery function in MOB indivi-
duals,7 the extent in the improvement in coronary circulatory
dysfunction did not correlate with the degree in weight loss or de-
crease in total fat amount after gastric bypass. The observation of
an absence of any correlation between the weight loss or decrease
in total fat amount and the normalization in coronary circulatory
function, respectively, most likely is also related to the striking
and non-linear decrease in body weight overriding the observed
improvement in coronary circulatory function. Of further interest,
improved hyperaemic MBFs with weight loss correlated mildly with
the decrease in plasma glucose levels. This may put forth that also a
mild increase in plasma glucose levels even when within the normal
range of plasma glucose levels may contribute to impairment in
hyperaemic MBFs in obesity. Altered glycaemic status associated
with weight loss, therefore, may reflect an important determinant
of coronary vascular homeostasis in non-diabetic obese individuals,
which merits further investigations.
As regards alterations in EC plasma levels, decreases in AEA
plasma levels owing to the gastric bypass-induced weight loss
Figure 2 (A) Correlation between the differences in Dlog anandamide (AEA) (ng/mL) and in myocardial blood flow (MBF) to cold pressor
testing (mL/g/min) between baseline and at the follow-up. (B) Correlation between the differences in Dlog adiponectin (ng/mL) and in
hyperaemic MBF (mL/g/min) between baseline and follow-up. SEE, Standard error of the estimate.
Figure 3 Correlation between differences in hyperaemic myo-
cardial blood flow (MBF) (mL/g/min) and in MBF to cold pressor
testing (mL/g/min) between baseline and follow-up. SEE, Standard
error of the estimate.
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were closely associated with the normalization in endothelium-
related MBF responses to CPT. As abnormal coronary circulatory
function has been recognized as a functional precursor of the CAD
process and future cardiovascular events,12 the observed associ-
ation between decreases in AEA plasma levels and the normaliza-
tion of coronary endothelial function after gastric-bypass-induced
weight loss provides further in vivo evidence that increases in
AEA plasma levels may reflect indeed a potential novel risk
factor for cardiovascular risk in obesity.4,5 Regarding the weight
loss-induced decrease in 2-AG plasma levels, however, we did
not observe an association neither with the normalization of
endothelium-related MBF responses nor with hyperaemic MBF
increases. Thus, it is possible that decreases in 2-AG plasma
levels contribute to the observed normalization of coronary circu-
latory function after weight loss only in concert with increases in
HDL and decreases in insulin resistance and inflammation. In this
regard, at least in viscerally obese men, lifestyle-induced reduction
of BMI and waist circumference has been demonstrated to cause
reductions in 2-AG levels that are directly correlated with
increases in HDL and decreases in insulin resistance.15 Independ-
ent of the exact molecular mechanisms of ECs altering the function
of the arterial wall, current and recent investigations4,5 put forth
that increases in EC plasma levels in obesity confer adverse
effects on coronary circulatory function.
In the current study in MOB individuals, we did not find a signifi-
cant or close association between alterations in lipid profile, insulin
resistance, triglycerides, and CRP plasma levels, and the normaliza-
tion of coronary circulatory function after gastric bypass-induced
weight loss as someone might have expected. The reason for
this astounding observation remains unclear but is likely to be
related to the relatively small sample size of MOB individuals
studied. Furthermore, in view of the striking decrease in gastric
bypass-induced total fat, which did lead to a normalization of cor-
onary circulatory function after a median FU of 22 months, it is also
possible that coronary circulatory function normalized before the
total decrease in fat amount was achieved. This, in fact, might also
have added to the observed dissociation between non-linear de-
crease in body weight and normalization in coronary circulatory
function after the FU, as also observed for flow-mediated brachial
artery function.7
Limitations
There are some limitations worthy of consideration. The current
investigation did not establish a causal relationship between
plasma levels of EC, adipocytokines, and obesity-related coronary
vasculopathy. Thus, further experimental investigations are certain-
ly needed to unmask the exact mechanisms of ECs and adipocyto-
kines in altering coronary circulatory function in obesity. In
addition, although no study participants had echocardiographic evi-
dence of left ventricular hypertrophy at baseline examination,
there is still a likely possibility that the observed improvement in
coronary circulatory function after weight loss may also be second-
ary to changes in cardiac remodelling,16 as opposed to a solely
primary effect on the function of the coronary circulation.
Finally, a multitude of comparisons are presented but in view of
the relatively low numbers of MOB individuals without adjustment
for multiplicity.
Conclusions
In this study, we have demonstrated a normalization of coronary
circulatory function related to a gastric bypass-induced weight
loss in MOB individuals. The associated decreases in AEA and
increases in adiponectin plasma levels were associated with the
normalization of coronary circulatory function after weight loss,
signifying that the (dys)balance between ECs and adipocytokines
may be seen as an important determinant of coronary circulatory
function in obesity. As an impairment of coronary circulatory func-
tion is commonly seen as a functional precursor of the CAD
process, its normalization after weight loss may reduce the associ-
ation between obesity and cardiovascular risk, which, however,
remains to be clinically tested.
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ST elevation myocardial infarction treated with bioresorbable vascular
scaffold: rationale and first cases
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Bioresorbable vascular scaffolds (BVS) have the
potential to start new era in interventional cardi-
ology. First clinical studies in stable coronary
artery disease have demonstrated a good safety
profile and promising results. The use of BVS in
ST elevation myocardial infarction (STEMI) has
not yet been reported.
The first two implantations of BVS Absorbw
during primary PCI for STEMI in humans
performed at our institution in December 2012
are described. Both patients have given written
informed consent. The first patient, a 54-year-
old male, presented with typical chest pain of
90 min duration, ST elevation in inferior leads
on ECG and thrombotic occlusion of the right
coronary artery. This lesion was predilated and
BVS Absorb 3.0/18 mm was implanted with
slow 1 Atm/s inflation to 16 Atm, angiographic result was optimal. Optical coherence tomography (OCT) performed with a Fourier-
domain, non-occlusive catheter (C7 Dragonfly, St Jude Medical, USA) demonstrated excellent BVS apposition to vessel wall and small
residual thrombi as the site of occlusion. Our second patient, a 52-year-old male, was admitted with anterior STEMI. Coronary angi-
ography demonstrated critical thrombotic stenosis of proximal left anterior descending (LAD) artery involving the origin of a diagonal
branch (Panel A). LAD was predilated with 3.0/12-mm balloon and subsequent slow flow in the diagonal branch was treated by ostial
dilatation with 2.5/15-mm balloon. Optical coherence tomography demonstrated a ruptured plaque beginning 8 mm proximal from
the diagonal branch (Panel B); a maximal thrombus burden was detected just proximal from the diagonal branch (Panel C). There
was no thrombus or ruptured plaque distal to diagonal branch. Bioresorbable vascular scaffold Absorb 3.5/28 mm was implanted
with 1 Atm/s inflation to 16 Atm for 30 s with optimal result (Panel D). Flow in the diagonal branch remained normal. Final OCT
demonstrated optimal scaffold apposition (longitudinal view on Panels E and F ), widely patent ostium of the diagonal branch with
clearly visible residual thrombi (Panel E) and perfect sealing of the ruptured plaque (Panel F). Both patients were treated with dual
antiplatelet therapy and in-hospital course was uneventful with discharge on Day 4.
The authors believe that primary PCI in the STEMI setting might represent a suitable BVS indication. Patients with STEMI tend to be
younger and any possible benefits of BVS are more likely to become evident with longer term follow-up. Despite the theoretical
advantages, there are no clinical data regarding safety of BVS in thrombotic lesions. It seems prudent to ensure that every BVS
implanted in highly thrombotic milieu is optimally expanded.
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